Randomized phase 2 trial of tremelimumab and durvalumab in combination versus sequentially in recurrent platinum‐resistant ovarian cancer is a research paper published in Cancer (2023). On theSindex it has a DataRank of 0. It has been cited 18 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
NIH HHS
Grant: CA016672
NCI NIH HHS
Grant: L30 CA123720
NCRR NIH HHS
Grant: M01 RR000847
NCI NIH HHS
Grant: P50 CA281701
NIH HHS
Grant: CA217685
NCI NIH HHS
Grant: P30 CA016672
NCI NIH HHS
Grant: P50 CA217685
NCI NIH HHS
Grant: R01 CA306089
NCI NIH HHS
Grant: T32 CA101642
NCI NIH HHS
Grant: K07 CA201013
FWCI
2.07
Citation Percentile
0.9%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals